Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06796543 · ClinicalTrials.gov registry record · NA
Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma
A NA study of Rhabdomyosarcoma and Ewing Sarcoma, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Recruiting
- Registry status
- NA
- Development phase
- 70
- Enrollment target
- 2
- Study locations
NCT06796543 is a NA study of Rhabdomyosarcoma and Ewing Sarcoma that is actively recruiting participants, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 70 participants, roughly in line with the 67-participant average among 35 other Rhabdomyosarcoma trials with a reported enrollment target. The trial reports 2 study locations across 2 states.
The verdict
NCT06796543, a NA study of Rhabdomyosarcoma and Ewing Sarcoma, is actively recruiting participants, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- RECRUITING
- Registry status
- NA
- Development phase
- 70 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is designed for children, adolescents and young adults undergoing radiation therapy for metastatic sarcoma. The aim of the study is to investigate if the investigators can improve the overall survival of these patients by targeting metastatic sites with radiation.
Conditions Studied
Interventions
- RADIATION Consolidative radiation therapy (cRT)
Study Locations (2)
District of Columbia
- Sibley Memorial Hospital - Washington D.C.
Maryland
- Johns Hopkins Hospital - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2025-03-25 |
| Est. Completion | 2030-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06796543
The ClinicalTrials.gov registry entry for NCT06796543 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 67-participant average among 35 other Rhabdomyosarcoma trials with a reported enrollment target. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Rhabdomyosarcoma appearing as the primary indexed condition, and to 1 intervention - of which Consolidative radiation therapy (cRT) is the first listed.
NCT06796543 reports 2 study locations spanning 2 distinct geographic areas - top geographies include District of Columbia, Maryland.
Frequently Asked Questions
What is clinical trial NCT06796543 about?
NCT06796543 is a clinical study titled "Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma". This study is designed for children, adolescents and young adults undergoing radiation therapy for metastatic sarcoma. The aim of the study is to investigate if the investigators can improve the overall survival of these patients by targeting metastatic sites with radiation.
What is the current status of trial NCT06796543?
This trial is currently recruiting. It is a NA study. The enrollment target is 70 participants. The study started on 2025-03-25. Estimated completion is 2030-03.
What conditions does trial NCT06796543 study?
This clinical trial studies the following conditions: Rhabdomyosarcoma, Ewing Sarcoma, Metastatic Sarcoma, Radiation Therapy Patient.
What interventions are being tested in trial NCT06796543?
The interventions under investigation include: Consolidative radiation therapy (cRT) (RADIATION).
Who is sponsoring clinical trial NCT06796543?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06796543 being conducted?
This trial has 2 study locations across District of Columbia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rhabdomyosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
RECRUITING · Phase 1
-
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
RECRUITING · Phase 1
-
Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.